Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of H SS or S-beta thalassemia~* History of at least one vaso-occlusive pain event in the 12 months prior to study entry~* Regular compliance with comprehensive medical care~* In a steady disease state and not in the midst of any acute complication due to SCD at study entry~Exclusion Criteria:~* Inability to take or tolerate oral medications~* Liver dysfunction (i.e., SGPT level greater than or equal to two times the normal limit and albumin level less than or equal to 3.2 g/dL)~* Kidney dysfunction ( i.e., creatinine level greater than or equal to 1.2 mg/dL for children and greater than or equal to 1.4 mg/dL for adults)~* Allergy to arginine~* Pregnant~* Received a blood transfusion within the 90 days prior to study entry~* More than 10 hospital admissions for pain in the 12 months prior to study entry~* Daily use of opioids and experiencing unstable pain that interferes with work or daily routine~* Required more than 3 hospital admissions and more than 10 emergency department/day hospital visits in the 12 months prior to study entry~* Received treatment with hydroxyurea within the 90 days prior to study entry~* Received treatment with any investigational drug in the 90 days prior to study entry

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: ACTIVE_COMPARATOR): 0.05 g/kg/day Arginine
- High Dose (Type: ACTIVE_COMPARATOR): 0.10 g/kg/day Arginine
- Placebo (Type: PLACEBO_COMPARATOR): No Arginine

Based on this trial design, predict the completion outcome and termination type (if applicable).